Howard Gurney
Howard Gurney
Macquarie University, Faculty of Medicine and Health Sciences
Verified email at
Cited by
Cited by
Nivolumab versus everolimus in advanced renal-cell carcinoma
RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ...
New England Journal of Medicine 373 (19), 1803-1813, 2015
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott, OA Frontera, B Melichar, ...
New England Journal of Medicine, 2018
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ...
New England Journal of Medicine 376 (11), 1015-1026, 2017
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ...
New England Journal of Medicine 380 (12), 1103-1115, 2019
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial
R Pettengell, H Gurney, JA Radford, DP Deakin, R James, PM Wilkinson, ...
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 …
BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ...
The Lancet 393 (10189), 2404-2415, 2019
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
H Gurney
Journal of Clinical Oncology 14 (9), 2590-2611, 1996
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised …
RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ...
The Lancet Oncology 20 (10), 1370-1385, 2019
How to calculate the dose of chemotherapy
H Gurney
British journal of cancer 86 (8), 1297-1302, 2002
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
JF Bishop, J Dewar, GC Toner, J Smith, MHN Tattersall, IN Olver, ...
Journal of Clinical Oncology 17 (8), 2355-2355, 1999
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ...
New England Journal of Medicine 383 (13), 1218-1230, 2020
Evidence for therapeutic drug monitoring of targeted anticancer therapies
B Gao, S Yeap, A Clements, B Balakrishnar, M Wong, H Gurney
Journal of Clinical Oncology 30 (32), 4017-4025, 2012
Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025
B Escudier, RJ Motzer, P Sharma, J Wagstaff, ER Plimack, HJ Hammers, ...
European urology 72 (3), 368-376, 2017
CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma
B Escudier, P Sharma, DF McDermott, S George, HJ Hammers, S Srinivas, ...
European urology 72 (6), 962-971, 2017
Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype
H Gurney, M Wong, RL Balleine, LP Rivory, AJ McLachlan, JM Hoskins, ...
Clinical Pharmacology & Therapeutics 82 (1), 33-40, 2007
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 years of follow-up
Y Fradet, J Bellmunt, DJ Vaughn, JL Lee, L Fong, NJ Vogelzang, ...
Annals of Oncology 30 (6), 970-976, 2019
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ...
New England Journal of Medicine 384 (14), 1289-1300, 2021
Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation
HP Gurney, S Ackland, V Gebski, G Farrell
Journal of clinical oncology 16 (7), 2299-2304, 1998
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
AM Hopkins, A Rowland, G Kichenadasse, MD Wiese, H Gurney, ...
British journal of cancer 117 (7), 913-920, 2017
Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer
NA Spry, L Kristjanson, B Hooton, L Hayden, G Neerhut, H Gurney, ...
European Journal of Cancer 42 (8), 1083-1092, 2006
The system can't perform the operation now. Try again later.
Articles 1–20